Skip to main content
OpenTrials
Completed

NCT Number: NCT05581550

Somatostatin Receptor Imaging in NPC, EBV Related Cancers

The study aims to describe the avidity of somatostatin receptors in locally advanced, metastatic and locally recurrent nasopharyngeal cancer (NPC) and to determine the proportion of NPC patients with high somatostatin receptor density that may benefit from future somatostatin targeted therapeutic trial plans. The investigators also aim to determine the presence of somatostatin receptors in other EBV related cancers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Nasopharyngeal Cancer Epstein-Barr Virus Related Carcinoma Head and Neck Neoplasms Nasopharyngeal Diseases Nasopharyngeal Neoplasms Neoplasms Neoplasms by Site Otorhinolaryngologic Diseases Otorhinolaryngologic Neoplasms Pharyngeal Diseases Pharyngeal Neoplasms Stomatognathic Diseases

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

National Cancer Centre Singapore

Singapore

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Locally advanced, metastatic or locally recurrent NPC that are going for FDG PET as part of their investigations
  • Patients that have gone for Ga-68 DOTATATE imaging before are eligible for repeat imaging
  • Histologically confirmed NPC
  • Above 21 years of age

Exclusion criteria

  • Patients below 21 years of age
  • Pregnant and breast feeding ladies

Treatment and study plan

FDG-PET

Radiation

Patients will be fasted for 6 hours prior to intravenous injection of 370MBq +/- 10% (18)F-fluorodeoxyglucose. Scanning will be performed at an interval of at least 60 minutes following the injection.

Galium-68 DOTATATE

Radiation

200MBq +/- 10% Galium-68 DOTATATE will be injected intravenously. Scanning will be performed approximately 60 minutes after the injection.

Primary outcomes

  1. Amount of tracer uptake in the tumour lesions of NPC patients

    Time frame: From time of tracer injection to time the scan is performed

    The maximum standardized uptake values (SUVmax) will be measured. If the average SUVmax of all the lesions is more than 10, the patient will be considered to have an overall high somatostatin receptor density.

Secondary outcomes

  1. Amount of tracer uptake in the tumour lesions of patients with EBV related cancers

    Time frame: From time of tracer injection to time the scan is performed

    The maximum standardized uptake values (SUVmax) will be measured. If the average SUVmax of all the lesions is more than 10, the patient will be considered to have an overall high somatostatin receptor density.

  2. Number of somatostatin receptors in patient biopsy samples

    Time frame: Upon signing the informed consent form

  3. Amount of somatostatin circulating tumour cells in patient blood samples

    Time frame: At the time of scan

Sponsors and collaborators

Lead sponsor

National Cancer Centre, Singapore

Other

Collaborators

  • National Cancer Centre Research Fund

Registry information

Official study title

Somatostatin Receptor Imaging in Nasopharyngeal Cancer, Epstein-Barr Virus (EBV) Related Cancers and Other Rare Tumors

Important dates

Study start
2020
Primary completion
2025
Study completion
2025
First posted
Oct 14, 2022
Registry last updated
Jul 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.